As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Big Pharma execs are finding homes in Chinese start-ups like BeiGene Ltd., where they are leveraging their industry knowledge and contacts to bring in deals focused on Asian populations.
You may also be interested in...
Merck Out-Licenses Gene Therapy Assets To FKD Therapies
Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.
Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
U.S.-China Hybrid Ascletis Helps Forge Stronger Ties Between China And North Carolina
U.S.-China hybrid Ascletis Inc. has reinforced ties between China and the U.S. under a memorandum of understanding signed July 16 with the Hangzhou Hi-Tech Industry Development Zone in Zhejiang Province, China, and The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina